| The state-of-play and future of antibody therapeutics Z Elgundi, M Reslan, E Cruz, V Sifniotis, V Kayser Advanced drug delivery reviews 122, 2-19, 2017 | 324 | 2017 |
| Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy E Cruz, V Kayser Biologics: targets and therapy, 33-51, 2019 | 197 | 2019 |
| Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation V Sifniotis, E Cruz, B Eroglu, V Kayser Antibodies 8 (2), 36, 2019 | 71 | 2019 |
| Synthesis and enhanced cellular uptake in vitro of anti-HER2 multifunctional gold nanoparticles E Cruz, V Kayser Cancers 11 (6), 870, 2019 | 39 | 2019 |
| Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry E Cruz, J Cain, B Crossett, V Kayser Human vaccines & immunotherapeutics 14 (3), 508-517, 2018 | 33 | 2018 |
| Demonstration of in vitro host-guest complex formation and safety of para-sulfonatocalix [8] arene as a delivery vehicle for two antibiotic drugs YE Moussa, YQE Ong, JD Perry, Z Cheng, V Kayser, E Cruz, RR Kim, ... Journal of pharmaceutical sciences 107 (12), 3105-3111, 2018 | 19 | 2018 |
| Claudin-5 binder enhances focused ultrasound-mediated opening in an in vitro blood-brain barrier model L Chen, R Sutharsan, JLF Lee, E Cruz, B Asnicar, T Palliyaguru, ... Theranostics 12 (5), 1952, 2022 | 18 | 2022 |
| Opportunities and challenges in delivering biologics for Alzheimer’s disease by low-intensity ultrasound L Chen, E Cruz, LE Oikari, P Padmanabhan, J Song, J Götz Advanced Drug Delivery Reviews 189, 114517, 2022 | 17 | 2022 |
| Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics. 2019; 13: 33-51 E Cruz, V Kayser Přejít k původnímu zdroji... Přejít na PubMed, 0 | 17 | |
| Ultrasound-mediated delivery of novel tau-specific monoclonal antibody enhances brain uptake but not therapeutic efficacy R Bajracharya, E Cruz, J Götz, RM Nisbet Journal of Controlled Release 349, 634-648, 2022 | 15 | 2022 |
| Enhancing the stability of adalimumab by engineering additional glycosylation motifs M Reslan, V Sifniotis, E Cruz, Z Sumer-Bayraktar, V Kayser International journal of biological macromolecules 158, 189-196, 2020 | 13 | 2020 |
| Laboratory scale production and purification of a therapeutic antibody Z Elgundi, V Sifniotis, M Reslan, E Cruz, V Kayser JoVE (Journal of Visualized Experiments), e55153, 2017 | 10 | 2017 |
| Therapeutic ultrasound as a treatment modality for physiological and pathological ageing including Alzheimer’s disease J Götz, G Richter-Stretton, E Cruz Pharmaceutics 13 (7), 1002, 2021 | 9 | 2021 |
| Structural biology workflow for the expression and characterization of functional human sodium glucose transporter type 1 in Pichia pastoris A Suades, A Alcaraz, E Cruz, E Álvarez-Marimon, JP Whitelegge, ... Scientific reports 9 (1), 1203, 2019 | 8 | 2019 |
| Single‐molecule imaging reveals Tau trapping at nanometer‐sized dynamic hot spots near the plasma membrane that persists after microtubule perturbation and cholesterol depletion P Padmanabhan, A Kneynsberg, E Cruz, R Amor, JB Sibarita, J Götz The EMBO Journal 41 (19), e111265, 2022 | 5 | 2022 |
| Glycan profile analysis of engineered trastuzumab with rationally added glycosylation sequons presents significantly increased glycan complexity E Cruz, V Sifniotis, Z Sumer-Bayraktar, M Reslan, L Wilkinson-White, ... Pharmaceutics 13 (11), 1747, 2021 | 3 | 2021 |
| Proteostasis as a fundamental principle of Tau immunotherapy E Cruz, RM Nisbet, P Padmanabhan, A van Waardenberg, ME Graham, ... bioRxiv, 2024.02. 12.580007, 2024 | 1 | 2024 |
| Major classes of biotherapeutics E Cruz, V Kayser Biologics, Biosimilars, and Biobetters: An Introduction for Pharmacists …, 2020 | 1 | 2020 |
| Single-molecule imaging of Tau reveals how phosphorylation affects its movement and confinement in living cells P Padmanabhan, A Kneynsberg, E Cruz, A Briner, J Götz Molecular Brain 17 (1), 7, 2024 | | 2024 |
| Break and accelerator—The mechanics of Tau (and amyloid) toxicity E Cruz, RM Nisbet, J Götz Cytoskeleton 81 (1), 24-29, 2024 | | 2024 |
